200 related articles for article (PubMed ID: 22473756)
1. Elevated serum IL-16 and RANTES levels in patients with autoimmune thyroid diseases and modulation by methimazole therapy.
Gu X; Zheng L; Chen X; Ruan L; Zhang H; Ge S; Zhu H; Lin X; Shen F
Horm Metab Res; 2012 Jun; 44(6):482-7. PubMed ID: 22473756
[TBL] [Abstract][Full Text] [Related]
2. Increase of interferon-gamma-inducible CXC chemokine CXCL10 serum levels in patients with active Graves' disease, and modulation by methimazole therapy.
Antonelli A; Rotondi M; Fallahi P; Romagnani P; Ferrari SM; Barani L; Ferrannini E; Serio M
Clin Endocrinol (Oxf); 2006 Feb; 64(2):189-95. PubMed ID: 16430719
[TBL] [Abstract][Full Text] [Related]
3. Influence of thyroxine on serum soluble interleukin-2 receptor alpha levels in thyroid disorders.
Zwirska-Korczala K; Berdowska A; Jochem J; Sitkiewicz A; Birkner E; Polaniak R; Jedrzejowska-Szypułka H; Korzonek-Szlacheta I
J Clin Pharm Ther; 2004 Apr; 29(2):151-6. PubMed ID: 15068404
[TBL] [Abstract][Full Text] [Related]
4. [Measurement of IL-12 and IL-18 in sera of patients with autoimmune thyroid disease].
Zhang JA; Zhang J; Xu L; Mar H; Wu XY
Xi Bao Yu Fen Zi Mian Yi Xue Za Zhi; 2006 Sep; 22(5):630-2. PubMed ID: 16948912
[TBL] [Abstract][Full Text] [Related]
5. Influence of methimazole and radioactive iodine treatment in the serum levels of the chemokine CXCL10 in hyperthyroid patients with Graves' disease.
Leite AC; Pedro AB; Romaldini JH
Horm Metab Res; 2011 Mar; 43(3):194-9. PubMed ID: 21283953
[TBL] [Abstract][Full Text] [Related]
6. Thyroid hormone modulates insulin-like growth factor-I(IGF-I) and IGF-binding protein-3, without mediation by growth hormone, in patients with autoimmune thyroid diseases.
Inukai T; Takanashi K; Takebayashi K; Fujiwara Y; Tayama K; Takemura Y
Horm Metab Res; 1999 Oct; 31(10):576-9. PubMed ID: 10596968
[TBL] [Abstract][Full Text] [Related]
7. Increase of interferon-γ inducible CXCL9 and CXCL11 serum levels in patients with active Graves' disease and modulation by methimazole therapy.
Antonelli A; Ferrari SM; Corrado A; Ferrannini E; Fallahi P
Thyroid; 2013 Nov; 23(11):1461-9. PubMed ID: 23721189
[TBL] [Abstract][Full Text] [Related]
8. 25-Hydroxyvitamin D serum level in Hashimoto's thyroiditis, but not Graves' disease is relatively deficient.
Ke W; Sun T; Zhang Y; He L; Wu Q; Liu J; Zha B
Endocr J; 2017 Jun; 64(6):581-587. PubMed ID: 28413173
[TBL] [Abstract][Full Text] [Related]
9. Serum levels of the interferon-gamma-inducible alpha chemokine CXCL10 in patients with active Graves' disease, and modulation by methimazole therapy and thyroidectomy.
Antonelli A; Fallahi P; Rotondi M; Ferrari SM; Serio M; Miccoli P
Br J Surg; 2006 Oct; 93(10):1226-31. PubMed ID: 16838393
[TBL] [Abstract][Full Text] [Related]
10. An elevation of serum immunoglobulin E provides a new aspect of hyperthyroid Graves' disease.
Yamada T; Sato A; Komiya I; Nishimori T; Ito Y; Terao A; Eto S; Tanaka Y
J Clin Endocrinol Metab; 2000 Aug; 85(8):2775-8. PubMed ID: 10946880
[TBL] [Abstract][Full Text] [Related]
11. Serum levels of cytokines in children and adolescents with Graves' disease and non-toxic nodular goiter.
Bossowski A; Urban M
J Pediatr Endocrinol Metab; 2001 Jun; 14(6):741-7. PubMed ID: 11453524
[TBL] [Abstract][Full Text] [Related]
12. Expression of Bcl-2 family proteins in thyrocytes from young patients with immune and nonimmune thyroid diseases.
Bossowski A; Czarnocka B; Bardadin K; Urban M; Niedziela M; Dadan J
Horm Res; 2008; 70(3):155-64. PubMed ID: 18663316
[TBL] [Abstract][Full Text] [Related]
13. Increases of the Th1/Th2 cell ratio in severe Hashimoto's disease and in the proportion of Th17 cells in intractable Graves' disease.
Nanba T; Watanabe M; Inoue N; Iwatani Y
Thyroid; 2009 May; 19(5):495-501. PubMed ID: 19415997
[TBL] [Abstract][Full Text] [Related]
14. Th1 and Th2 serum cytokine profiles characterize patients with Hashimoto's thyroiditis (Th1) and Graves' disease (Th2).
Phenekos C; Vryonidou A; Gritzapis AD; Baxevanis CN; Goula M; Papamichail M
Neuroimmunomodulation; 2004; 11(4):209-13. PubMed ID: 15249726
[TBL] [Abstract][Full Text] [Related]
15. Serum CD40/CD40L system in Graves' disease and Hashimoto's thyroiditis related to soluble Fas, FasL and humoral markers of autoimmune response.
Mysliwiec J; Oklota M; Nikolajuk A; Waligorski D; Gorska M
Immunol Invest; 2007; 36(3):247-57. PubMed ID: 17558708
[TBL] [Abstract][Full Text] [Related]
16. Serum CXCL10 levels and neuromuscular manifestations in patients with autoimmune thyroid diseases.
Cakir M; Levendoglu F; Kiyici A; Coskun Y
Autoimmunity; 2011 Sep; 44(6):496-503. PubMed ID: 21457060
[TBL] [Abstract][Full Text] [Related]
17. Decreased nerve growth factor levels in hyperthyroid Graves' ophthalmopathy highlighting the role of neuroprotective factor in autoimmune thyroid diseases.
Molnár I; Bokk A
Cytokine; 2006 Aug; 35(3-4):109-14. PubMed ID: 17008110
[TBL] [Abstract][Full Text] [Related]
18. Metamorphic thyroid autoimmunity in Down Syndrome: from Hashimoto's thyroiditis to Graves' disease and beyond.
Aversa T; Valenzise M; Salerno M; Corrias A; Iughetti L; Radetti G; De Luca F; Wasniewska M
Ital J Pediatr; 2015 Nov; 41():87. PubMed ID: 26558364
[TBL] [Abstract][Full Text] [Related]
19. Down-regulation of the auto-aggressive processes in patients with hypothyroid Hashimoto's thyroiditis following substitutive treatment with L-thyroxine.
Guclu F; Ozmen B; Kirmaz C; Kafesciler SO; Degirmenci PB; Taneli F; Hekimsoy Z
Eur Cytokine Netw; 2009 Mar; 20(1):27-32. PubMed ID: 19318318
[TBL] [Abstract][Full Text] [Related]
20. [The assessment of usefulness of humoral markers estimation in patients with autoimmune thyroid diseases].
Myśliwiec J; Okłota M; Nikołajuk A; Górska M
Pol Merkur Lekarski; 2005 Nov; 19(113):663-6. PubMed ID: 16498807
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
